SecSonar.com

Takeda Pharmaceutical Company Limited (TAK)

Takeda Pharmaceutical Company Limited at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Takeda Pharmaceutical Company Limited (TAK) is a Drug Manufacturers - Specialty & Generic company based in JP with a market capitalization of $50.4B. Revenue grew 4.3% year-over-year and the company generated $5B in free cash flow. This page tracks TAK's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

JP · 49.28K employees · IPO Jan 5, 2010

Valuation

Valuation & price

$16.61 · as of May 17, 2026 · -11.6% vs 52w high

0.3

P/E ratio

Latest-FY diluted EPS

0.01

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$18.74$16.09$13.44Jul 25Dec 25Jul 26Jul 7, 25$15.07Jul 9, 25$15.13Jul 11, 25$14.68Jul 15, 25$14.75Jul 17, 25$14.74Jul 21, 25$14.44Jul 23, 25$14.74Jul 25, 25$14.48Jul 29, 25$14.32Jul 31, 25$13.72Aug 4, 25$14.26Aug 6, 25$14.27Aug 11, 25$14.43Aug 13, 25$14.77Aug 15, 25$15.00Aug 19, 25$15.20Aug 21, 25$15.31Aug 25, 25$15.07Aug 27, 25$14.86Aug 29, 25$14.99Sep 3, 25$15.15Sep 5, 25$15.40Sep 9, 25$15.27Sep 11, 25$15.34Sep 16, 25$15.12Sep 18, 25$15.02Sep 22, 25$15.01Sep 24, 25$14.96Sep 26, 25$14.74Sep 30, 25$14.64Oct 2, 25$14.44Oct 6, 25$14.55Oct 8, 25$14.31Oct 10, 25$13.71Oct 14, 25$13.80Oct 16, 25$13.88Oct 21, 25$14.11Oct 23, 25$14.06Oct 27, 25$14.17Oct 29, 25$13.77Oct 31, 25$13.44Nov 4, 25$13.56Nov 6, 25$13.64Nov 10, 25$13.71Nov 12, 25$14.09Nov 14, 25$14.29Nov 18, 25$14.07Nov 20, 25$14.06Nov 25, 25$14.50Nov 28, 25$14.42Dec 2, 25$14.29Dec 4, 25$14.28Dec 8, 25$14.22Dec 10, 25$14.37Dec 12, 25$14.33Dec 16, 25$14.53Dec 18, 25$14.83Dec 22, 25$15.10Dec 24, 25$15.58Dec 29, 25$15.76Jan 2, 26$15.62Jan 6, 26$15.79Jan 8, 26$16.37Jan 12, 26$16.26Jan 14, 26$16.47Jan 16, 26$16.16Jan 21, 26$16.08Jan 23, 26$16.29Jan 27, 26$16.91Jan 29, 26$17.17Feb 2, 26$17.49Feb 4, 26$17.74Feb 9, 26$17.73Feb 11, 26$18.28Feb 13, 26$18.46Feb 18, 26$18.54Feb 20, 26$18.66Feb 24, 26$18.65Feb 26, 26$18.53Mar 2, 26$18.44Mar 4, 26$18.22Mar 6, 26$17.88Mar 10, 26$18.21Mar 12, 26$17.77Mar 17, 26$18.39Mar 19, 26$18.11Mar 23, 26$17.86Mar 25, 26$18.29Mar 27, 26$17.91Mar 31, 26$18.52Apr 2, 26$18.74Apr 7, 26$18.29Apr 9, 26$18.46Apr 13, 26$17.82Apr 15, 26$17.85Apr 17, 26$17.82Apr 22, 26$16.60Apr 24, 26$16.63Apr 28, 26$16.41Apr 30, 26$16.68May 4, 26$16.56May 6, 26$16.72May 8, 26$16.46May 12, 26$16.42May 14, 26$16.63May 18, 26$16.57May 20, 26$16.68May 22, 26$16.25May 28, 26$16.15Jun 1, 26$15.19Jun 3, 26$15.03Jun 5, 26$15.60Jun 9, 26$15.72Jun 11, 26$15.87Jun 15, 26$15.77Jun 17, 26$15.42Jun 22, 26$15.47Jun 24, 26$15.72Jun 26, 26$15.91Jul 2, 26$16.77
$13.2352-week range$18.80
Loading valuation history…

Fundamentals

Key fundamentals

$50.4B

Market cap

4.3%

Revenue growth (YoY)

51.1%

Gross margin

$5B

Free cash flow (USD)

$4.3T

Net debt

-1.9%

Share dilution

4/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2017 → 2026

FY 2017$1732.1BFY 2018$1770.5BFY 2019$2097.2BFY 2020$3291.2BFY 2021$3197.8BFY 2022$3569.0BFY 2023$4027.5BFY 2024$4263.8BFY 2025$4581.6BFY 2026$4777.5B
$1.7T$4.8T

Free cash flow by year

2017 → 2026

FY 2017$149.3BFY 2018$249.6BFY 2019$194.4BFY 2020$452.0BFY 2021$774.5BFY 2022$937.1BFY 2023$343.5BFY 2024$235.6BFY 2025$856.4BFY 2026$808.7B
$149.3B$808.7B

Gross margin by year

2022 → 2026

FY 202269.0%FY 202369.1%FY 202466.4%FY 202565.5%FY 202651.1%
69.0%51.1%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed Jun 26, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingArticles of IncorporationJun 29, 2026Filing
  • Annual reportAnnual Report FiledJun 26, 2026Filing
  • Annual reportAnnual Report FiledJun 24, 2026Filing
  • 6-K filingManagement ChangeJun 24, 2026Filing
  • Annual reportAnnual Report FiledJun 24, 2026Filing
  • Annual report20-F FiledJun 17, 2026Filing
  • 6-K filingShare Issuance AnnouncementJun 9, 2026Filing
  • Annual reportAnnual Report FiledJun 5, 2026Filing
  • Annual reportAnnual Report FiledJun 5, 2026Filing
  • 6-K filingShelf Registration UpdateJun 1, 2026Filing

Questions

Frequently asked questions

What is Takeda Pharmaceutical Company Limited's market cap?

Takeda Pharmaceutical Company Limited (TAK) has a market capitalization of $50.4B.

What is TAK's P/E ratio?

TAK trades at a price-to-earnings ratio of 0.3, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is TAK's price-to-book (P/B) ratio?

TAK trades at 0.01 times book value per share.

Are insiders buying TAK stock?

SEC Form 4 filings show no open-market insider buys at Takeda Pharmaceutical Company Limited in the last 90 days (0 sells).

Same arena

Related companies in Drug Manufacturers - Specialty & Generic

HLN

Haleon plc

$40.5B

TEVA

Teva Pharmaceutical Industries Limited

$40.4B

VTRS

Viatris Inc.

$18.8B

ELAN

Elanco Animal Health Incorporated

$12B

RDY

Dr. Reddy's Laboratories Limited

$11.4B

LNTH

Lantheus Holdings, Inc.

$6.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.